Zevra Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), before Tax
Zevra Therapeutics, Inc. (ZVRA) reported Foreign Currency Transaction Gain (Loss), before Tax of $1.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-05
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $406.00K, a 395.12% increase year-over-year.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was $1.40M.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$1.42M.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was $5.00K, a 87.80% decline year-over-year.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2025 was -$1.55M.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$219.00K, a 210.61% decline from fiscal 2023.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2023 was $198.00K, a 117.58% increase from fiscal 2022.
- Zevra Therapeutics, Inc. foreign currency transaction gain (loss), before tax for fiscal 2022 was $91.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $406.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.81M 10-Q · filed 2026-08-05 | $387.00K derived: sum of 3 quarters · filed 2026-08-05 | $392.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-06 | -$19.00K derived: sum of 2 quarters · filed 2026-05-06 | -$14.00K derived: sum of 3 quarters · filed 2026-05-06 | $68.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.42M derived: sum of 2 quarters · filed 2026-03-09 | -$1.33M derived: sum of 3 quarters · filed 2026-08-05 | -$1.55M 10-K · filed 2026-03-09 |
| 2025-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $87.00K derived: sum of 2 quarters · filed 2026-08-05 | -$126.00K 10-Q · filed 2025-11-05 | -$198.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$131.00K 10-Q · filed 2026-08-05 | -$203.00K derived: sum of 3 quarters · filed 2026-08-05 | -$162.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$213.00K 10-Q · filed 2026-05-06 | -$285.00K derived: sum of 2 quarters · filed 2026-05-06 | -$244.00K derived: sum of 3 quarters · filed 2026-05-06 | -$203.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$31.00K derived: sum of 2 quarters · filed 2026-03-09 | $10.00K derived: sum of 3 quarters · filed 2026-03-09 | -$219.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $82.00K derived: sum of 2 quarters · filed 2025-11-05 | -$147.00K 10-Q · filed 2025-11-05 | $21.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$188.00K 10-Q · filed 2025-08-12 | -$20.00K derived: sum of 3 quarters · filed 2025-08-12 | -$128.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$229.00K 10-Q · filed 2025-05-13 | -$61.00K derived: sum of 2 quarters · filed 2025-05-13 | -$169.00K derived: sum of 3 quarters · filed 2025-05-13 | -$271.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $60.00K derived: sum of 2 quarters · filed 2025-03-12 | -$42.00K derived: sum of 3 quarters · filed 2025-03-12 | $198.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | -$108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$210.00K derived: sum of 2 quarters · filed 2024-11-13 | $30.00K 10-Q · filed 2024-11-13 | $121.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $138.00K 10-Q · filed 2024-08-14 | $229.00K derived: sum of 3 quarters · filed 2024-08-14 | $229.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $240.00K 10-Q · filed 2024-05-09 | $331.00K derived: sum of 2 quarters · filed 2024-05-09 | $331.00K derived: sum of 3 quarters · filed 2024-05-09 | $331.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $91.00K derived: sum of 2 quarters · filed 2024-04-01 | $91.00K derived: sum of 3 quarters · filed 2024-04-01 | $91.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |